Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial

Table 3 Participants reporting at least one serious adverse event from Day 0 to Day 179 in the total vaccinated cohort

	AS03_C	AS03_C-MPL25	AS03_C-MPL50	AS03_B	AS03_B-MPL25	AS03_B-MPL50	AS03_A	AS03_A-MPL25	Non-adjuvanted ≥65 y	Non-adjuvanted 18–40 y
	N=204	N=202	N=198	N=202	N=199	N=199	N=202	N=198	N=200	N=203
Day 0–21	0 (0.0%)	2 (1.0%)	2 (1.0%)	3 (1.5%)	2 (1.0%)	4 (2.0%)	2 (1.0%)	4 (2.0%)	0 (0.0%)	0 (0.0%)
Day 21–179	18 (8.8%)	8 (4.0%)	16 (8.1%)	9 (4.5%)	9 (4.5%)	19 (9.5%)	5 (2.5%)	10 (5.1%)	15 (7.5%)	3 (1.5%)

All participants received inactivated trivalent influenza vaccine, non-adjuvanted (≥65 years and 18–40 years) or formulated with an adjuvant. AS03 is a squalene and α-tocopherol oil-in-water emulsion-based Adjuvant System, with tocopherol content 11.86 mg (A), 5.93 mg (B), or 2.97 mg (C); MPL is 3-O-desacyl-4’- monophosphoryl lipid A: 25 μg (MPL-25) or 50 μg (MPL-50).

ISSN: 1471-2334